NCT00251355View on ClinicalTrials.gov

Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Non-Metastatic Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 1998

Primary Completion Date

June 30, 2007

Study Completion Date

August 31, 2008

Conditions
Pancreatic Cancer
Interventions
DRUG

Gemcitabine

Gemcitabine, IV bolus administered weekly (weeks 1-6) at least 4 hours before that day's radiation therapy.

DRUG

5-Fluorouracil

5-FU via continuous IV infusion.

PROCEDURE

Radiation Therapy

External Beam Radiotherapy (weeks 1-6), Monday through Friday.

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Massachusetts General Hospital

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT00251355 - Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Non-Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter